- Recent Funding
- Investors
- Health2047 Capital Partners
Health2047 Capital Partners portfolio
Health2047 Capital Partners has 1 portfolio company on record at Recent Funding. Its most recent investment on record is Chapter's $42M Series B+ round in January 2022, alongside XYZ Venture Capital, Susa Ventures, Narya Capital and 3 others. That company is in Insurance. It has co-invested with Maverick Ventures, Susa Ventures and XYZ Venture Capital, most often Maverick Ventures (2 rounds).
What Health2047 Capital Partners invests in
- Insurance · 1 · 100%
- Health and bio · 1 · 100%
How Health2047 Capital Partners invests
Share is of the 2 rounds on Recent Funding that name Health2047 Capital Partners. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Health2047 Capital Partners portfolio companies
| Company | Round with Health2047 Capital Partners | Total raised | Latest raise |
|---|---|---|---|
Insurance |
Series B+ · $42M | $284M | Apr 9, 2026 Series B+ |
Most frequent co-investors
MMaverick Ventures2 shared rounds · last Jan 11, 2022SSusa Ventures2 shared rounds · last Jan 11, 2022
XXYZ Venture Capital2 shared rounds · last Jan 11, 2022
CCore Innovation Capital2 shared rounds · last Jan 11, 2022
NNarya Capital2 shared rounds · last Jan 11, 2022
AAddition1 shared round · last Jan 11, 2022
PPeter Thiel1 shared round · last Sep 21, 2021
Similar investors
AAccelia Capital1 company · 1 deal in 12 mo
AAngel Academe1 company · 1 deal in 12 mo
BBioGenerator Ventures1 company · 1 deal in 12 mo
BBiospring Partners1 company · 1 deal in 12 mo
CColossa Ventures1 company · 1 deal in 12 moDDeepWork Capital1 company · 1 deal in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Insurance).
Portfolio companies are the companies on Recent Funding with a round that lists Health2047 Capital Partners, which is a subset of its real portfolio. API: /api/v1/investors/health2047-capital-partners (get a free API key). More: the most active VC firms and new venture capital funds.